• Most Popular
  • Most Shared

Intercell Q2 revenue rises, net loss halves

Mon Aug 18, 2008 1:45am EDT

Stocks

   

VIENNA, Aug 18 (Reuters) - Austrian biotech firm Intercell (ICEL.VI) reported second-quarter revenue that more than doubled to 9 million euros ($13 million), due to an increase in revenue from collaboration and licensing, it said on Monday. The net loss roughly halved to 4 million euros in the three months to June. The company reiterated it expected positive net income in the full year, despite its acquisition of U.S. biotech group Iomai IOMI.O.

The company, whose main product is a vaccine against Japanese encephalitis, expected to win market approval later this year, had no major product announcement in its statement.

Swiss drug form Novartis (NOVN.VX) is Intercell's biggest shareholder with a 16-percent stake. (Reporting by Boris Groendahl; Editing by Erica Billingham)



More from Reuters

Photo

Jobless claims hit 17-month low

WASHINGTON (Reuters) - The number of U.S. workers filing new applications for jobless benefits fell last week to the lowest level in about 17 months, suggesting the economy might be on the cusp of job creation.

» More Top News
Traders work in the pits at the The New York Mercantile Exchange, November 7, 2007. REUTERS/Brendan McDermid

Calling the market

A spectacular credit bust, two devastating stock market crashes ... the smart call this decade was to play it safe.  Full Article 

Global Markets
People walk past a branch of Bank of America in New York's financial district April 28, 2009. REUTERS/Brendan McDermid
Rolfe Winkler:

Move your money

Boycotting "too big to fail" banks is a great idea -- so long as investors remember that banks aren't the only ones responsible for the crisis.  Full Article 

    Commentary